1446176-65-3

Upstream product

• 880157-10-8 benzyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate 
• 1446176-58-4 6-[4-fluoro-3-(methoxycarbonyl)phenyl]-3-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid 
• 1446176-55-1 benzyl 1-benzyl-6-[4-fluoro-3-(methoxycarbonyl)phenyl]-1H-pyrazolo[3,4-b]pyridine-4-carboxylate 
• 1446176-54-0 benzyl 1-benzyl-6-chloro-1H-pyrazolo[3,4-b]pyridine-4-carboxylate 
• 1446176-53-9 1-benzyl-6-chloro-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid 
• 74439-45-5 ethyl 1-benzyl-6-hydroxy-1H-pyrazolo[3,4-b]pyridine-4-carboxylate 
• 1446176-52-8 ethyl 1-benzyl-6-chloro-1H-pyrazolo[3,4-b]pyridine-4-carboxylate 

Downstream Products

• 1446176-66-4 methyl 5-[3-{3-[(benzyloxy)carbonyl]phenyl}-4-carbamoyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-b]pyridin-6-yl]-2-fluorobenzoate 
• 1446176-67-5 3-{4-carbamoyl-6-[4-fluoro-3-(methoxycarbonyl)phenyl]-1H-pyrazolo[3,4-b]pyridin-3-yl}benzoic acid 

Relevant academic research and scientific papers

FGF RECEPTOR (FGFR) AGONIST DIMERIC COMPOUNDS, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF

The invention relates to novel heterocyclic compounds which are pyrazolopyridine derivatives that induce fibroblast growth factor receptor (FGFR) dimerization, having the general formula: M1-L-M2 in which M1 or M2, which may be identical or different, each represent, independently of one another, a monomer unit M and L represents a linker group which links M1 and M2 covalently with the monomer unit which follows: Process for the preparation thereof and therapeutic use thereof.